Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 2Plasmacytoma 1Paraproteinemias 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 140Lenalidomide 60Bortezomib 56Calcium Dobesilate 48Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10isatuximab 9Cyclosporine 9pembrolizumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × filanesib × Plasma cell × Clear all
NCT02384083 2022-07-27

Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients

PETHEMA Foundation

Phase 1/2 Completed
47 enrolled
Plasma cell

Multiple Myeloma

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡